AnaptysBio, Inc.
- ANAB
- NASDAQ
- Biotechnology
- Immunology Biotech
- Antibody Therapeutics
- Clinical-Stage
$46.61
Today −4.31%Quote Oct 16, 2026, 08:00 PM UTC
−15.35%over the last month
Max drawdown −17.4%From 1-month high −15.6%3 months −7.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.39B
Quote Oct 16
Next earnings
Nov 3
Expected, not confirmed
Analyst target
$79.17
+69.9% from here
Floor
$43.85
5.9% below price
Where the price sits
23 analysts
Analyst range, low to high
$70.00$95.00
- Price $46.61
- Resistance $46.84
- Consensus $79.17
The price is right under resistance. Analysts' average target sits about 70% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ANABPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
104
Founded
2005